Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection:: A practical guide for health care professionals

被引：9

作者：

Cote, Pierre ^{[1
,2
]}

Baril, Jean-Guy ^{[1
,2
]}

Hebert, Marie-Nicole

Klein, Marina

Lalonde, Richard

Poliquin, Marc ^{[2
]}

Rouleau, Danielle ^{[2
]}

Therrien, Rachel ^{[2
]}

Vezina, Sylvie ^{[2
]}

Willems, Bernard ^{[2
]}

Dion, Harold ^{[3
]}

Junod, Patrice ^{[2
]}

Lapointe, Normand ^{[4
]}

Levesque, Dominic ^{[5
]}

Pinault, Lyse ^{[6
]}

Tremblay, Cecile ^{[2
]}

Trottier, Benoit ^{[2
]}

Trottier, Sylvie ^{[7
]}

Tsoukas, Chris

Piche, Alain ^{[8
]}

机构：

[1] Clin Med Quartier Latin, Montreal, PQ H2L 5B1, Canada

[2] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[3] Coll Quebecois Med Famille, Quebec Coll Family Phys, Quebec City, PQ, Canada

[4] Hop St Justine, Ctr Maternel & Infantile Sida, Montreal, PQ, Canada

[5] Comite Personnes Atteintes VIH Quebec CPAVIH, Montreal, PQ, Canada

[6] Coalit Organismes Communautaires Quebecois Lutte, COCQ Sida, Montreal, PQ, Canada

[7] Ctr Hosp Univ Quebec, Ste Foy, PQ, Canada

[8] Ctr Hosp Univ Sherbrooke, Sherbrooke, PQ, Canada

来源：

CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY | 2007年 / 18卷 / 05期

关键词：

antiretrovirals; coinfection; hepatitis C virus; HIV; practical guide; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-2A PLUS RIBAVIRIN; INFECTED PATIENTS; NATURAL-HISTORY; ANTIRETROVIRAL THERAPY; RISK-FACTORS; DOSE PHARMACOKINETICS; SEVERE HEPATOTOXICITY; PROTEASE INHIBITOR; LACTIC-ACIDOSIS;

D O I：

10.1155/2007/631054

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Concomitant HIV and hepatitis C virus (HCV) is a common yet complex coinfection. The present document is a practical guide for treating HCV infection in people coinfected with HIV. Effective anti-retroviral therapies have prolonged survival rates for HIV-infected people over the past decade, which have made latent complications of HCV major causes of morbidity and mortality in these patients. Advances in the treatment of HCV (eg, combined pegylated interferon and ribavirin) offer the possibility of eradicating HCV infection in coinfected persons. The treatment of HCV must be considered in all cases. Intensive management of the adverse effects of HCV treatment is one of the factors for the success of these therapies. HCV eradication is predicted to decrease the mortality associated with coinfection and reduce the toxicity of HIV treatment.

引用

页码：293 / 303

页数：11

共 90 条

[1] Chronic hepatitis C with normal aminotransferase levels [J].

Ahmed, A ;

Keeffe, EB .

GASTROENTEROLOGY, 2004, 126 (05) :1409-1415

[2] Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients [J].

Alberti, A ;

Clumeck, N ;

Collins, S ;

Gerlich, W ;

Lundgren, J ;

Palù, G ;

Reiss, P ;

Thiebaut, R ;

Weiland, O ;

Yazdanpanah, Y ;

Zeuzem, S .

JOURNAL OF HEPATOLOGY, 2005, 42 (05) :615-624

[3]

ALTFELD M, 2005, HIV MED, pS3

[4]

ALVAREZ D, 2005, 12 C RETR OPP INF BO

[5]

ARANZABAL L, 2004, 7 INT C DRUG THER HI

[6]

ARRIBAS J, 2003, 8 EUR AIDS C VARS OC

[7]

BARIL JG, 2002, ANTIRETROVIRAL THERA, P93

[8]

BARREIRO P, 2004, 7 INT C DRUG THER HI

[9] Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion [J].

Beld, M ;

Penning, M ;

van Putten, M ;

van den Hoek, A ;

Damen, M ;

Klein, MR ;

Goudsmit, J .

BLOOD, 1999, 94 (04) :1183-1191

[10] Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy [J].

Benhamou, Y ;

Di Martino, V ;

Bochet, M ;

Colombet, G ;

Thibault, V ;

Liou, A ;

Katlama, C ;

Poynard, T .

HEPATOLOGY, 2001, 34 (02) :283-287

← 1 2 3 4 5 6 7 8 9 →